The effects of Omega-3 and nano-curcumin on migraine disorder

The combined effects of omega3 fatty acids and curcumin supplementation on Oxidative Stress in migraine patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015073123434N1

Enrollment

Registered

2017-07-23

Start date

2013-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine without aura

Interventions

Intervention 1: Group 1: receiving omega-3 fatty acids capsules, 1250 twice per day with lunch, for 2 months and nano-curcumin capsule, 80 mg once per day with dinner for 2 months. Intervention 2: Gro

Treatment - Drugs

Placebo

Group 1: receiving omega-3 fatty acids capsules, 1250 twice per day with lunch, for 2 months and nano-curcumin capsule, 80 mg once per day with dinner for 2 months

Group 2: receiving omega-3 fatty acids capsules, 1250 twice per day with lunch, for 2 months and placebo of nano-curcumin capsule, 80 mg included oral paraffin once per day with dinner for 2 months

Group 3: receiving nano-curcumin capsule, 80 mg once per day with dinner for 2 months and placebo of omega-3 fatty acids capsules, 1250 mg included oral paraffin twice per day with lunch, for 2 month

group 4 (control): receiving placebo of omega-3 fatty acids capsules, 1250 mg included oral paraffin twice per day with lunch, for 2 months and placebo of nano-curcumin capsule, 80 mg included oral pa

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 20-50; patients with episodic migraine; any other disorders; avoidance of consumption of supplements or vitamins at least 4-6 weeks before intervention and during study; any use of special diet, supplements of activity. Exclusion criteria: Allergic reaction to omega-3 or nano-curcumin compounds; Cancel of patient from cooperation; pregnancy; any sever changes in diet, usual lifestyle or taking drugs; any inflammatory disorders that have to take anti-inflammatory drugs (more than 2 weeks).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum levels of Malondialdehyde. Timepoint: before and after 2 months intervention. Method of measurement: ELISA (Pg/ml).;Serum levels of Glutathione peroxidase. Timepoint: before and after 2 months intervention. Method of measurement: ELISA (Pg/ml).;Serum levels of Superoxide dismutase. Timepoint: before and after 2 months intervention. Method of measurement: ELISA (Pg/ml).	—

Secondary

Measure	Time frame
Body Mass Index. Timepoint: befor and after 2 months intervention. Method of measurement: calculating from weight (kg)/height (m2).;Weight. Timepoint: befor and after 2 months intervention. Method of measurement: Scales (kg).;Waist circumference. Timepoint: befor and after 2 months intervention. Method of measurement: tape meter (cm).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mina A bdolahi

Faculty of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences

m-abdolahi@razi.tums.ac.irabdolahimina.n@gmail.com+98 21 8895 5975

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026